Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.934 – $1.02
Volume52,754
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.34M
Price / earnings
—
Price / book
0.28×
Price / sales
4.34×
EV / sales
-1.23×
EV / EBITDA
0.14×
Profitability
Earnings per share
-$2.88
Return on assets
-57.04%
Return on equity
-83.44%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.91×
Quick ratio
7.91×
Cash ratio
2.21×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.9M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KPRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1M
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1M
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.58M
$1.38M
$1.61M
$1.46M
$1.44M
$1.35M
$1.49M
$1.33M
Research and development
$1.95M
$2.08M
$2.12M
$2.93M
$2.73M
$2.59M
$2.53M
-$83.66K
Total operating expenses
$2.69M
$2.21M
$2.51M
$7.31M
$794.44K
$2.4M
$2.33M
$2.56M
Operating income
-$1.69M
-$2.21M
-$2.51M
-$7.31M
-$794.44K
-$2.4M
-$2.33M
-$2.56M
Interest expense
$0
$146.23K
$0
-$19.96K
$0
$225.24K
$0
-$21.45K
Income before taxes
-$1.58M
-$2.08M
-$2.42M
-$7.17M
-$616.32K
-$2.26M
-$2.07M
-$2.16M
Income taxes
$165K
$0
$0
-$649.97K
-$643.13K
-$112.06K
$123.01K
$2.07M
Net income
-$1.75M
-$2.08M
-$2.42M
-$6.52M
$26.81K
-$2.15M
-$2.19M
-$4.22M
Net income attributable to common shareholders
-$1.75M
-$2.08M
-$2.42M
-$6.52M
$26.81K
-$2.15M
-$2.19M
-$4.22M
EBITDA
-$1.68M
-$2.2M
-$2.5M
-$2.68M
-$783.89K
-$2.39M
-$2.33M
-$550.77K
Basic earnings per share
-$0.28
-$0.34
-$0.58
-$1.56
$0.01
-$0.54
-$0.52
-$1.00
Diluted earnings per share
-$0.28
-$0.34
-$0.58
-$1.69
$0.01
-$0.54
-$0.52
-$1.00
Recent news
Company coverage with links to the original publishers.
The article discusses the advancements in gene therapy for Stargardt disease, a genetic eye disorder, and highlights the significant investment and interest in developing long-term treatments. It mentions over 20 companies working on 25+ pipeline drugs to improve the treatment landscape.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
HC Wainwright & Co. has decided to maintain its Buy rating of Kiora Pharmaceuticals (NASDAQ:KPRX) and raise its price target from $3.50 to $2.00.
Shares of Kiora Pharmaceuticals are trading down 0.84% over the last 24 hours, at $0.66 per share.
A move to $2.00 would account for a 202.57% increase from the current share price.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in ...Full story available on Benzinga.com
Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results.
Skechers said fourth-quarter revenue increased 4.4% year-over-year to $1.96 billion, which missed the consensus estimate of $2.03 billion, according to Benzinga Pro. The company reported quarterly earnings of 56 cents per share, which beat analyst estimates of 54 cents per share.
Skechers shares fell 6.9% to $59.21 on Friday.
Here are some other stocks moving in today's mid-day session.
Gainers
Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares jumped 77.6% to $4.28. Intelligent Bio Solutions said it sees preliminary second-quarter revenue of $0.76 million.
Minim, Inc. (NASDAQ: MINM) shares rose 34.4% to $6.76 after gaining more than 22% on Thursday.
Remark Holdings, Inc. (NASDAQ: MARK) shares climbed 33% to $0.6802.
Kopin Corporation (NASDAQ: KOPN) jumped 30% to $2.4050.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) rose 26.3% to $2.73.
Mountain Crest Acquisition Corp. IV (NASDAQ: MCAF) gained 23% to $14.65.
Tyra Biosciences, Inc. (NASDAQ: TYRA) gained 21.8% to $15.84. Tyra Biosciences announced a $200 million private placement financing.
Meta Platforms, Inc. (NASDAQ: META) rose 18.9% to $469.34 as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share.
CCSC Technology International Holdings Limited (NASDAQ: CCTG) gained 18.2% to $4.6099 after dipping around 82% on Thursday.
Roma Green Finance Limited (NASDAQ: ROMA) gained 15.8% to $0.8697 after gaining around 5% on Thursday.
Deckers Outdoor Corporation (NYSE: DECK) surged 14% to $879.03 after reporting better-than-expected third-quarter financial results.
Trugolf, Inc. (NASDAQ: TRUG) shares jumped 14% to ...
Shares of Meta Platforms, Inc. (NASDAQ: META) rose sharply in today’s pre-market trading as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share.
The company also announced a $50 billion increase to its share repurchase authorization.
Meta shares climbed 16.5% to $460.02 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers
CCSC Technology International Holdings Limited (NASDAQ: CCTG) gained 55.1% to $6.05 in pre-market trading after dipping around 82% on Thursday.
Trugolf, Inc. (NASDAQ: TRUG) shares jumped 33.1% to $1.77 in pre-market trading after dipping 55% on Thursday.
Roma Green Finance Limited (NASDAQ: ROMA) gained 25.2% to $0.94 in pre-market trading after gaining around 5% on Thursday.
Jiuzi Holdings, Inc. (NASDAQ: JZXN) shares gained 20% to $0.84 in pre-market trading.
C3is Inc. (NASDAQ: CISS) shares rose 18.8% to $0.1625 in pre-market trading. S.H.N. Financial recently reported a 9.1% stake in the company.
Minim, Inc. (NASDAQ: MINM) shares rose 18.7% to $5.97 in pre-market trading after gaining more than 22% on ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.